Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Trial Profile

An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Mobilised-peripheral-blood-cells (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellect Biotechnology
  • Most Recent Events

    • 05 Feb 2019 According to a Cellect Biotechnology media release, additional interim results are expected during the first half of 2019, and topline results by the end of the year. Company expectS to complete recruitment during the second quarter of 2019.
    • 23 Jan 2019 According to a Cellect Biotechnology media release, following the completion of this study, which is expected to conclude by the end of the second quarter of 2019, and following the 180-day evaluation period, the company expects to report topline results in late 2019 or early 2020.
    • 23 Jan 2019 According to a Cellect Biotechnology media release, announcement of further interim data from this trial is an upcoming milestone target through June 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top